FHLC vs VHT

Key Takeaways

• Both FHLC and VHT are passively managed, market-capitalization-weighted funds tracking nearly identical MSCI U.S. health care indexes, making their exposure profiles almost interchangeable.
• The two ETFs share essentially the same top holdings, led by LLY, JNJ, and ABBV, so differences in returns are driven mainly by cost and minor holding counts rather than strategy.
• FHLC charges a slightly lower expense ratio (0.08%) than VHT (0.09%), a marginal but durable cost advantage for long-term investors.
• VHT offers greater scale, deeper trading liquidity, and a longer track record (launched in 2004), while FHLC launched in 2013.
• Both funds concentrate in pharmaceuticals, biotechnology, and health care equipment, exposing investors to the same sector-level catalysts and risks.
• Tickeron AI Verdict: Given near-identical exposure, FHLC edges ahead on cost efficiency, making it the AI-preferred choice.

Introduction

For investors seeking broad U.S. health care exposure, the Fidelity MSCI Health Care Index ETF (FHLC) and the Vanguard Health Care ETF (VHT) are two of the most direct competitors available. Both funds track the same MSCI health care index family and hold essentially the same securities, which makes this a pure "cost and structure" comparison rather than a debate over differing strategies. As health care remains a defensive, innovation-driven corner of the market, understanding the subtle distinctions between these two funds helps investors select the more efficient vehicle for capturing the sector's long-term growth.

Fidelity MSCI Health Care Index ETF (FHLC) Overview

FHLC is a passively managed index ETF that seeks to track the MSCI USA IMI Health Care 25/50 Index, which represents the U.S. health care sector across large-, mid-, and small-capitalization companies. The fund holds roughly 330 securities and applies a market-capitalization weighting methodology with a 25/50 concentration constraint designed to limit single-stock and issuer concentration.

Its top holdings are heavily concentrated in large-cap pharmaceuticals and managed care, including LLY (approximately 13%), JNJ (around 8.8%), ABBV, UNH, and MRK. By industry, pharmaceuticals account for roughly 32% of assets, followed by biotechnology (about 22%), health care equipment and supplies (around 19%), and providers and services (about 16%). The fund carries a net expense ratio of 0.08%, among the lowest in the health care category, and launched in October 2013.

Vanguard Health Care ETF (VHT) Overview

VHT tracks the MSCI US Investable Market Health Care 25/50 Index, a near-identical benchmark that also spans U.S. large-, mid-, and small-cap health care stocks using market-cap weighting with the same 25/50 concentration rules. The fund holds approximately 420 to 425 securities, giving it a marginally wider small-cap tail than FHLC.

Its largest positions mirror those of FHLC: LLY, JNJ, ABBV, UNH, and MRK dominate, with pharmaceuticals, biotechnology, and equipment making up the bulk of exposure. The fund's expense ratio is 0.09%, and it was launched in January 2004, giving it one of the longest operating histories in the health care ETF space as well as substantial assets under management (AUM) and deep trading liquidity.

Industry and Thematic Backdrop

The U.S. health care sector is currently shaped by several powerful, long-duration forces. Innovation in GLP-1 obesity and diabetes treatments, oncology, and gene therapy continues to drive earnings growth for large-cap pharmaceutical and biotechnology names, while an aging population supports structural demand for providers, equipment, and managed care services. At the same time, regulatory scrutiny over drug pricing, Medicare and Medicaid policy shifts, and litigation risk in managed care create recurring headline volatility. Health care's historically defensive characteristics have also attracted capital during periods of broader equity-market uncertainty, though rising interest rates can weigh on the valuation of longer-duration, innovation-heavy holdings. Both FHLC and VHT sit squarely at the center of these catalysts and risks.

Performance and Positioning Comparison

Because FHLC and VHT track the same index family with near-identical top holdings, their fund performance and relative positioning have moved almost in lockstep across recent weeks and market cycles. Both funds have benefited from the same sector rotation into health care, driven by strong earnings from large-cap pharmaceutical leaders and renewed defensive positioning. Any divergence between the two is typically measured in single basis points and stems from the one-basis-point expense gap and VHT's slightly broader small-cap exposure. Volatility profiles are effectively equivalent, meaning investors choosing between them are selecting a vehicle rather than a distinct investment thesis.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore the AI Screener to refine your own sector-level research.

Tickeron AI Verdict

When two ETFs are as structurally similar as FHLC and VHT, the tiebreaker falls to observable, durable factors rather than short-term price momentum. Tickeron's AI would likely favor FHLC on the basis of its lower expense ratio (0.08% versus 0.09%), which compounds into a measurable cost advantage over long holding periods despite near-identical exposure. While VHT offers marginally greater scale, liquidity, and historical tenure, these benefits are less relevant to a long-term, buy-and-hold investor than recurring cost. The assessment is probabilistic and rooted in cost efficiency and structural alignment rather than any predicted price move.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations